FcRH5 (FCRL5)
FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.
Overview
FCRL5 encodes Fc receptor-like 5, a B-lineage surface receptor expressed on mature B cells and retained on plasma cells; on myeloma cells expression is near-universal and higher than on normal counterparts, in part through 1q21 gain where the gene sits. Cevostamab, a FcRH5 x CD3 bispecific antibody, is in late-stage trials for relapsed and refractory multiple myeloma; no approval names the antigen yet.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.
- 1 · What it is
FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.
- 2 · What goes wrong in cancer
A type I transmembrane protein with immunoglobulin-like domains that modulates B-cell receptor signalling; its restricted lineage expression, like BCMA and GPRC5D, is what makes it a T-cell redirection target.
- 3 · How drugs use it
No product in this corpus aims at FcRH5 (FCRL5) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
External identifiers
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
Biology
A type I transmembrane protein with immunoglobulin-like domains that modulates B-cell receptor signalling; its restricted lineage expression, like BCMA and GPRC5D, is what makes it a T-cell redirection target.
- Multiple myeloma (near-universal on plasma cells)
- B-cell lymphomas and chronic lymphocytic leukaemia
Latest papers
topQuery for this target: (TITLE:"FcRH5" OR ABSTRACT:"FcRH5" OR TITLE:"FCRL5" OR ABSTRACT:"FCRL5" OR TITLE:"FCRH5" OR ABSTRACT:"FCRH5" OR TITLE:"IRTA2" OR ABSTRACT:"IRTA2" OR TITLE:"CD307e" OR ABSTRACT:"CD307e" OR TITLE:"Fc receptor-like 5" OR ABSTRACT:"Fc receptor-like 5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FcRH5 (FCRL5), not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
- TrialA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
- BiomarkerGPRC5D expression
Shares FcRH5 expression, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag surface-antigen.
- BiomarkerBCMA expression
Shares FcRH5 expression, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag surface-antigen.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
- TrialHuman BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
- TrialA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Shares Cevostamab, Multiple myeloma.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.